|
MMP3 genotypes vs clinical, pathological and epidemiological variables |
||||
| Variables |
MMP3 -1171 5A/6A |
|||
| 5A5A |
5A6A |
6A6A |
p-value* |
|
|
|
||||
| Stage at Diagnosis |
||||
| 0 |
9 (16%) |
36 (63%) |
12 (21%) |
|
| I |
96 (19%) |
238 (48%) |
162 (33%) |
|
| II |
32 (14%) |
124 (54%) |
75 (33%) |
|
| III |
27 (16%) |
81 (49%) |
57 (35%) |
|
| IV |
2 (22%) |
5 (56%) |
2 (22%) |
0.36 |
| Primary Clark Level |
||||
| I |
9 (16%) |
36 (63%) |
12 (21%) |
|
| II |
22 (21%) |
54 (51%) |
29 (28%) |
|
| III |
28 (19%) |
73 (49%) |
47 (32%) |
|
| IV |
72 (15%) |
241 (50%) |
165 (35%) |
0.36 |
| V |
9 (13%) |
39 (57%) |
21 (30%) |
0.04£ |
| Thickness (mm) |
||||
| In situ |
9 (16%) |
36 (63%) |
12 (21%) |
|
| < 1.01 |
60 (19%) |
150 (48%) |
105 (33%) |
|
| 1.01 – 2.00 |
45 (17%) |
132 (49%) |
90 (34%) |
|
| 2.01 – 4.00 |
28 (18%) |
78 (49%) |
53 (33%) |
|
| > 4.00 |
12 (10%) |
71 (60%) |
35 (30%) |
0.16 |
| TILs |
||||
| Absent |
28 (14%) |
101 (50%) |
73 (36%) |
|
| Non-brisk |
65 (17%) |
208 (54%) |
114 (30%) |
0.32 |
| Brisk |
4 (13%) |
20 (65%) |
7 (23%) |
0.04£ |
| Distant Metastasis |
||||
| Yes |
21 (16%) |
69 (54%) |
39 (30%) |
|
| No |
148 (17%) |
428 (50%) |
277 (33%) |
0.84 |
| Intransit Metastasis |
||||
| No |
160 (17%) |
468 (51%) |
296 (32%) |
|
| Yes |
6 (22%) |
12 (44%) |
9 (33%) |
0.80 |
| Number of Moles |
||||
| None |
41 (16%) |
136 (53%) |
79 (31%) |
|
| Few |
87 (18%) |
240 (49%) |
165 (34%) |
|
| Moderate |
27 (17%) |
87 (54%) |
48 (30%) |
|
| Many |
9 (23%) |
21 (53%) |
10 (25%) |
0.76 |
| Phenotypic Index |
||||
| 1 (low risk) |
6 (16%) |
15 (41%) |
16 (43%) |
|
| 2 |
28 (14%) |
105 (51%) |
73 (35%) |
|
| 3 |
59 (19%) |
157 (50%) |
98 (31%) |
|
| 4 |
59 (18%) |
172 (54%) |
89 (28%) |
|
| 5 (high risk) |
18 (18%) |
47 (46%) |
38 (37%) |
0.36 |
|
*The associations were examined in three different ways (see statistical methods for a detailed explanation). The p-values shown refer to the analysis of the three individual genotypes, and appear in bold font if ≤ 0.05. The significance was lost after adjustment for age, sex, phenotypic index, moles, freckles, and race. £Genotypes 5A6A and 6A6A combined. | ||||
Cotignola et al. Journal of Negative Results in BioMedicine 2007 6:9 doi:10.1186/1477-5751-6-9 |
||||